Mylan loses Lipidil appeal, despite court finding proof of intention not needed for Swiss-style claims

Intellectual Property 2020-07-03 5:27 pm | Sydney
Mylan Health has lost its challenge to a ruling that invalidated three patents related to its blockbuster cholesterol drug Lipidil, despite the appeals court finding the primary judge had erred by ruling that proof of intention was required for Swiss-style claims.
For information on rights and reprints, contact subscriptions@lawyerly.com.au